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Smith, MD; Robert H. Rosenwasser, MD, MBA, FACS, FAHA; Pascal Jabbour, MD
Department of Neurological Surgery, Thomas Jefferson University and Jefferson Hospital
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ABSTRACT
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10
days before pipeline aneurysm treatment. Our study assessed the safety and efficacy
of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device
(PED) treatment.
Methods: In this retrospective cohort study, we included patients treated with PED
from October 2010 to May 2016. A total of 39.7% (n = 158) of patients were dispensed
a loading dose of 650 mg of aspirin plus at least 600 mg of clopidogrel 24 hours
preceding PED deployment, compared to 60.3% (n = 240) of patients who received
81-325 mg of aspirin daily for 10 days with 75 mg of clopidogrel daily preprocedurally.
The mean follow-up was 15.8 months (standard deviation [SD] 12.4 months). modified
Rankin Scale (mRS) was registered before the discharge and at each follow-up visit. To
control confounding, we used multivariable logistic regression and propensity score
conditioning.
Results: Of 398 patients, the proportion of female patients was ~16.5% (41/240) in
both groups and shared the same mean of age ~56.46 years. ~12.2% (mean = 0.09;
SD = 0.30) had a subarachnoid hemorrhage. 92% (mean = 0.29; SD = 0.70) from the
pretreatment group and 85.7% (mean = 0.44; SD = 0.91) of the bolus group had a
mRS ≤2. In multivariate analysis, bolus did not affect the mRS score, P = 0.24. Seven
patients had a long-term recurrence, 2 (0.83%; mean = 0.01; SD = 0.10) of which from
the pretreatment group. In a multivariable logistic regression, bolus was not associated
with a long-term recurrence rate (odds ratio [OR] 1.91; 95% confidence interval [CI]
0.27-13.50; P = 0.52) or with thromboembolic accidents (OR 0.99; 95% CI 0.96-1.03;
P = 0.83) nor with hemorrhagic events (OR 1.00; 95% CI 0.97-1.03; P = 0.99). Three
patients died: one who received a bolus had an acute subarachnoid hemorrhage.
The mean mortality rate was parallel in both groups ~0.25 (SD = 0.16). Bolus was not
associated with mortality (OR 1.11; 95% CI 0.26-4.65; P = 0.89). The same associations
were present in propensity score-adjusted models.
Conclusions: In a cohort receiving PED, a 600-mg loading dose of clopidogrel should
be safe and efficacious in those off the standard protocol or showing <30% platelet
inhibition before treatment.

INTRODUCTION
Pipeline embolization device (PED; Covidien, Irvine, California, USA) has become an
integral tool in the treatment of intracranial aneurysms. Since its approval by the Food
and Drug Administration in 2011, studies have publicized remarkable occlusion rates
with this endoluminal device.1 Antiaggregation drugs are dispensed during and after the
pipeline deployment procedure to reduce the likelihood of thromboembolic events.2
A single loading dose of aspirin or clopidogrel is neither safe nor sufficient in reducing
PED-related thromboembolic complications.3 Patients suffering from cerebrovascular
aneurysms and selected for a flow diversion treatment should receive a dual antiplatelet
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therapy (DAPT) of aspirin and clopidogrel
for a minimum of 7-10 days before the
intervention.4 Even at a high maintenance
dose, patients continue to show variability
in the degree of platelet inhibition.5
The key in approaching cerebral
aneurysms is in assuring an optimal
>50% platelet inhibition with the right
choice of antiplatelet medication and
by keeping the platelet-reactive units
(PRUs) between 194 and 416 (adopted in
our center).6 Although a standard 75-mg
dose of clopidogrel produces an irreversible P2Y12 platelet receptor blockade, its
72-hour delayed maximal action is one
of its major limitations.7 A bolus of 600
mg of clopidogrel must be administered
to overcome the previous limitation and
achieve a rapid and more potent platelet
inhibition within 24 hours before the
pipeline deployment.8 The central aim of
this study was to evaluate the safety and
the efficacy of a 600-mg loading dose of
clopidogrel when given 24 hours before
PED deployment to protect patients from
thromboembolic events during and after
their procedure.

METHODS
Study Population
This was a retrospective cohort study of
all patients undergoing a PED treatment
for their cerebrovascular aneurysms in a
tertiary referral center between October
2010 and May 2016. A total of 398
consecutive patients undergoing pipeline
flow diversion were included. The mean
age of the population was 56.46 years
(min = 16 years, max = 81 years). Only 2
patients were minors at 16 and 17 years
old. The study protocol was reviewed
and approved by the institutional review
board. Patient consent was not needed
because of the retrospective nature of
the study. A total of 23 of 398 patients
presented with ruptured aneurysm.
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Treatment Protocol

Outcome Variables

Patients treated with the PED were
analyzed retrospectively and separated
into two groups of standard of care
treatment, i.e., 158 (39.7%) patients were
administered a DAPT bolus of 650 mg
of aspirin plus at least 600 mg of clopidogrel within the 24 hours preceding
their procedure and 240 (60.3%) patients
(227 with aspirin, 9 with coumadin, 4
with rivaroxaban) received the standard
protocol of 81-325 mg of aspirin daily
with 75 mg of clopidogrel daily for 7-10
days before their intervention. Patients
included in both groups were recruited
subsequent to an incidental finding
of their aneurysm on routine neuroimaging or to a screening magnetic
resonance angiography prescribed
because of first-degree family history
of aneurysms. Others had symptoms
related to the aneurysm: worst headache
of life, Horner syndrome, worsening
headache, ophthalmoplegia, dizziness,
tinnitus, blurry vision, diplopia, and retroorbital pain. A total of 23 (5.8%) patients
were admitted urgently and diagnosed
with a subarachnoid hemorrhage (SAH)
secondary to aneurysm rupture: 6 (26%)
were pretreated with aspirin and clopidogrel, and 1 7 (74%) was administered
a bolus of DAPT as described previously.

The key primary outcomes were thromboembolic event incidence (minor:
transient deficit or asymptomatic stroke
documented on diffusion-weighted
imaging; major: clinically measurable
deficit) including pre- and postprocedural
thrombus formation and hemorrhagic
accidents with subsequent tangible and
concrete clinical deficit (not including
the asymptomatic sulcal SAH as seen
on routine postoperational computed
tomography) after pipeline deployment.
Early and late postprocedural hemorrhagic and thromboembolic events
were included. Modified Rankin Scale
(mRS) score, calculated and registered
before the discharge of the patients and
at each follow-up visit, mortality rates,
intrapipeline stenosis due to overt neoendothelialization, postinterventional length
of stay, and the long-term recurrence
were all considered secondary outcomes.

We regularly calculated the P2Y12 PRU
score using P2Y12 assays (VerifyNow;
Accumetrics, San Diego, California, USA)
for all patients before the procedure.
Prasugrel (n = 20) was considered if the
patients were allergic, nonresponders, or
resistant to clopidogrel. Resistance was
defined with <30%, PRU <194 of platelets’
P2Y12 receptor inhibition with antiplatelet
drugs. Ticagrelor (n = 2) was adopted in
patients labeled as non- responders or
allergic to prasugrel. Patients with inhibition >90% had their procedure canceled,
and clopidogrel was held until the platelet
inhibition level fell below 90%. Patients
were continued afterword on 75 mg of
clopidogrel daily or 5-10 mg of prasugrel
daily or 90 mg twice a day of ticagrelor
daily. Vitals and neurologic examination
were monitored in the intensive care unit,
and patients were deescalated to the
floor after 24 hours of clinical well-being.
Prophylactic antiplatelet therapy was
given as a minimum of 6 months to 1 year
after the procedure, followed by aspirin
indefinitely (Figure 1).
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Patient Follow-Up
Follow-up visits were scheduled with
the senior author after 1, 3, 6, and
18 months after their discharge from

Incidental
cerebral aneurysm

the institution. The efficacy and the
safety of the aspirin/clopidogrel bolus
dispensed within 24 hours preceding
the pipeline treatment was evaluated
on initial postoperative angiography.
Cerebrovascular angiography (digital
subtraction angiography) was required
at the 6-month visit, and then patients
were followed accordingly to evaluate
for bleeding recurrence or vessel
stenosis. Computed tomography
scans of the head were compared
and analyzed by the senior author
to document any new or recurrent
subarachnoid or intraparenchymal
hemorrhage only if the patients
developed new insidious symptoms.
Medical charts were reviewed to
determine whether any retroperitoneal, gastrointestinal, or genitourinary
bleeding had occurred.
Exposure Variables
The primary exposure variable was the
treatment (clopidogrel pretreatment vs.
clopidogrel bolus). Covariates used for
risk adjustment were age and sex. The
comorbidities used for risk adjustment

Ruptured
cerebral aneurysm

Symptomatic
cerebral aneurysm

Patient scheduled for
PED treatment

Within <7 days

Within <7 days

Give IV-Bolus
600mg clopidogrel
+
650mg aspirin 24hrs
before the procedure

Re-check PRU,
proceed with
PED deployment
as scheduled

Give
75mg clopidogrel OD
+
81-325mg aspirin OD
for 7-10 days

PRU Test<194
&/or P2Y12
platelets inhibition
score<30%

PRU Test 194 to 416 &/
or P2Y12
platelets inhibition
score 30-90%

PED deployment
as scheduled

Figure 1. Decision tree graph of the antiaggregation Pipeline Embolization Device;
PRU, platelet-reactive protocol adopted before pipeline deployment. PED, unit.
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Table 1. Patient characteristics
Bolus
Age (years)

p value

Yes (n=158)

No (n=240)

56.77 (13.70)

56.15 (13.04)

0.51

Male gender

84.2%

82.9%

0.30

Hypertension

0.53 (0.50)

0.49 (0,50)

0.83

Smoking

0.52 (0.50)

0.49 (0,50)

0.31

Aneurysm size (mm)

9.58 (6.84)

9.23 (6.04)

2.86

Previous SAH*

0.10 (0.30)

0.10 (0.23)

0.92

Adjunctive Coiling

0.12 (0.33)

0.04 (0.20)

0.75

Balloon use

0.07 (0.26)

0.07 (0.26)

0.90

*SAH, subarachnoid hemorrhage.

were hypertension, diabetes mellitus,
smoking, previous SAH, aneurysm
size, per-procedural balloon, previous
coiling. This manuscript adheres to the
Strengthening the Reporting of Observational studies in Epidemiology (i.e.,
STROBE) Statement: guidelines for
reporting observational studies.
Statistical Analysis
For binary outcomes we used a multivariable logistic regression, controlling
for all the covariates mentioned previously. To control for clustering at the
physician level, we used mixed effect
models with physician as a random
effects variable. For continuous
outcomes, we used the corresponding
linear regression analyses.
In an alternate way to control for
confounding for binary outcomes,
we used a propensity score adjusted
logistic regression model. To derive
the propensity of receiving a bolus, we
developed a prediction model using
logistic regression, based on all the
covariates described previously. We
subsequently used a logistic regression with adjustment (stratification)
by quantiles (we chose the number of
quantiles to be 10) of the propensity
score. Operating physician was again
used as a random effects variable.
Patients who were lost to follow-up
were not included in the original
analysis. In sensitivity analysis, all
the aforementioned analyses were
repeated used multiple imputations
for the patients lost to follow-up.
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Regression
diagnostics
were
performed for all analyses. Given that
the long-term recurrence was 2% in a
study sample of 437 patients, we had
an 80% power to detect a difference
in long-term recurrence as small as
13.4%, at an α-level of 0.05. All probability values were the result of two
sided tests. Stata version 13 (StataCorp,
College Station, Texas, USA) was used
for statistical analysis.

RESULTS
Demographic Characteristics
Between October 2010 and May 2016,
398 patients underwent treatment with
PED in our institution. The proportion of
female patients was 17.1% (41/240) in the
pretreatment group and 15.8% (25/158)
in the bolus group (P = 0.30). Patients in
the pretreatment group shared a similar
mean of age with the bolus group (56.15
years; 56.77 years), respectively (P =
0.510). The mean aneurysm size was 9.22
mm (standard deviation [SD] = 6.04) in
the pretreatment group and 9.58 mm (SD
= 6.84) in the bolus group (P = 2.86). The
proportion of patients with a history of
previous SAH (not presenting with acute
SAH) was 11.7% (28/240; mean = 0.09;
SD = 0.30) in the pretreatment group,
whereas it was 12.7% (20/158; mean =
0.10; SD = 0.30) in the bolus group (P =
0.92). Likewise, both groups had the same
average 1.21 (min = 1 PED, max = 4 PED)
number of pipelines used per patient. The
fraction of patients receiving adjunctive
coiling was 4.6% (11/240; mean = 0.41;

SD = 0.19) in the pretreatment group
versus 13.3% (20/158; mean = 0.12; SD
= 0.33) in patients receiving the loading
dose of antiaggregate medication (P =
0.75). Balloon angioplasty was needed in
approximately 9.7% (22/240; 16/158) of
patients in both groups (P = 0.90). Nine
of 158 patients from the bolus group
presented with aneurysm rupture and a
subsequent SAH and required an immediate intervention with a loading dose of
clopidogrel. A total of 139 of 158 patients
were included because of nonresponsiveness or resistance to the standard
10 days DAPT antiaggregation protocol.
The mean monthly follow-up for the
patients was 15.8 months (SD = 12.36). A
total of 398 patients were identified at our
institution, and they constituted our study
population. The characteristics of the
cohort at baseline are disclosed in Table 1.

Safety of a Loading Dose of
Clopidogrel
Thromboembolic Complications. Of 398

patients, 15 (6.3%; mean = 0.05; SD =
0.23) patients receiving the pretreatment protocol had thromboembolic
complications, and 17 (10.8%; me
an = 0.12; SD = 0.32) patients from
the bolus group suffered from these
complications (Table 2). A univariate
analysis comparing the use of a bolus
of clopidogrel with the thromboembolic complication rate did not
show any correlation between the 2
variables (odds ratio [OR], 0.99; 95%
confidence interval [CI] 0.96-1.03; P
= 0.83). We found similar results in a
multivariable mixed-effects logistic
regression bolus (OR 0.99; 95% CI
0.96-1.03; P = 0.81) and a propensity
score-adjusted model (OR 0.99; 95%
CI 0.96-1.03; P = 0.82).
Hemorrhagic Complications. Of 398

patients, 9 (3.75%; mean = 0.25; SD =
0.16) (Table 2) patients receiving the
pretreatment protocol had hemorrhagic complications, and 12 (7.6%;
mean = 0.08; SD = 0.27) patients from
the bolus group suffered from these
complications. The mean of hemorrhagic complications in the global
population was 0.48 (SD = 0.21). A
univariate analysis comparing the
use of a bolus of clopidogrel with the
hemorrhagic complication rate did not
show any correlation between the 2

3

variables (OR 0.99; 95% CI 0.97-1.03;
P = 0.87). In a multivariable mixedeffects logistic regression, bolus (OR
1.00; 95% CI 0.97-1.03; P = 0.99) was
not associated with an increased
hemorrhagic event rate. We found
similar results with the propensity
score adjusted model (OR 0.99; 95%
CI 0.96-1.03; P = 0.87).
Long-Term Recurrence. Of 398,
7 (1.76%; mean = 0.02; SD = 0.15)
patients had a long-term recurrence: 2
(0.83%; mean = 0.01; SD = 0.10) from the
pretreatment group versus 5 (3.16%;
mean = 0.03; SD = 0.18) patients in
the bolus group. A univariate analysis
comparing the use of a bolus of clopidogrel to the long-term recurrence
rate did not show any correlation
between the 2 variables (OR 3.32; 95%
CI 0.60-18.43; P = 0.17). In a multivariable mixed-effects logistic regression,
bolus (OR 1.91; 95% CI 0.27-13.50; P =
0.52) was not associated with a longterm recurrence rate. This finding was
consistent with the propensity scoreeadjusted model (OR 3.00; 95% CI
0.51-17.58; P = 0.22) (Table 3).
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Mortality. Of 398 patients, 9 patients
expired: 6 patients died from various
non-PED related events such as severe
sepsis (1), malignant hypertension with
a large middle cerebral artery infarct
(1), severe gastro-intestinal complication (1), and non-reported (3). Only
three patients were announced dead
secondary to cerebrovascular complications: one patient from the bolus
group died from acute SAH, and two
patients from the pretreatment group
died from severe intraparenchymal
hemorrhage. The mean of mortality
rate in the global population was
0.02 (SD = 0.15), 0.25 (SD = 0.16) in
the pretreatment group, and 0.26 (SD
= 0.16) in the bolus group (Table 2).
A univariate analysis comparing the
use of a bolus of clopidogrel to the
mortality rate did not show any correlation between the two variables (OR
0.99; 95% CI 0.77-1.30; P = 0.95). In
a multivariable mixed-effects logistic
regression, bolus (OR 1.11; 95% CI
0.26-4.65; P = 0.89) was not associated with an increased mortality rate.
This finding persisted in a propensity

score-adjusted model (OR 0.99; 95%
CI 0.89-1.11; P = 0.92).

Table 2. Mean Value and Standard Deviation of Outcomes
Pre-treatment

Bolus

Total

mean(SD*)

mean(SD*)

mean(SD*)

.11 (0.10)

.34 (0.2)

.21 (0.14)

Intra-PED stenosis

.07 (0.26) n=17

0.07 (0.26) n=10

.07 (0.26)

Thromboembolic acc.

.54 (0.23) n=2

.12 (0.32) n=5

.07 (0.26)

Hemorrhagic acc.

.25 (0.16)

.10 (0.28

.41 (0.28)

Mortality

.25 (0.16)

.25 (0.16)

.02 (0.15)

Length of stay(days)

1.69 (2.81)

2.11 (3.2)

1.86 (2.96)

mRS at last follow-up

.44 (0.91)

.29 (0.7)

.36 (0.79)

Outcomes
Long-term recurrence

Efficacy of the Loading Dose of
Clopidogrel
Intrapipeline Stenosis. Of 398 patients,
27 (6.8%; mean = 0.75; SD = 0.26) had an
intra-PED stenosis with 17 (7.08%; mean =
0.72; SD = 0.26) in the pretreatment group
and 10 (6.32%; mean = 0.76; SD = 0.27)
in the bolus group. A univariate analysis
comparing the use of a bolus of clopidogrel with the intrapipeline stenosis rate
did not show any correlation between the
two variables (OR 1.07; 95% CI 0.45-2.55;
P = 0.88). In a multivariate mixed-effects
logistic regression, bolus (OR, 0.90; 95%
CI 0.36-2.30; P = 0.89) was not associated with higher intra-PED stenosis rate.
This was coherent with the propensity
score-adjusted model. (OR 0.92; 95% CI
0.37-2.34; P = 0.88).
Latest Clinical Status. In the global population, the mean mRS was 0.36 (SD = 0.79);
it was 0.44 (SD = 0.91) in the bolus group
and 0.29 (SD = 0.70) in the pretreatment
group. A total of 87.8% of the global population, 92% of the pretreatment group and
85.7% of the bolus group had a mRS 2. In a
multivariate analysis were the latest mRS is
a dependent variable, bolus did not affect
the latest mRS score, P = 0.24 (Table 3).
Postinterventional Hospital Stay. In the
global population, the mean postoperational hospital stay was 1.86 days (SD =
2.96): 1.69 days (SD = 2.81) in the pretreatment group and 2.11 days (SD = 3.2) in
the bolus group. In a multivariate analysis
in which the postinterventional stay is a
dependent variable, bolus did not affect
the postoperational hospital stay, P = 0.64.

*SD, standard deviation; PED, Pipeline Embolization Device; acc., accident; mRS, modified Rankin Scale.

Table 3. Aassociation Between Outcomes and Clopidogrel Bolus
Models

Long-term recurrence

Intra-PED stenosis

Thromboembolic

Hemorrhagic

Mortality

OR*(CI95%) p value

OR*(CI95%) p value

OR*(CI95%) p value

OR*(CI95%) p value

OR*(CI95%) p value

Multi-variable
logistic regression

1.9 1
(.27 to 13.50)

0.517

0.90
(.36 to 2.29)

0.83

0.99
(.96 to 1.03)

0.81

1.00
(.97 to 1.03)

0.99

1.11
(.26 to 4.65)

0.89

Propensity score

3.00
(.513 to 17.58)

0.22

0.928
(.37 to 2.34)

0.88

0.99
(.96 to 1.03)

0.82

0.99
(.97 to 1.03)

0.87

0.99
(.89 to 1.11)

0.92

*OR, odds ratio; CI, confidence interval.
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DISCUSSION
Using a retrospective cohort of patients
treated for their cerebrovascular
aneurysm(s), we did not find any association between a clopidogrel 600-mg
loading dose and increased mortality
rate, thromboembolic accidents, longterm recurrence, intrapipeline stenosis,
hemorrhagic events, mRS on last followup, and postoperational length of stay.
The elevated risk of acute and delayed
thromboembolic complications associated with the PED necessitates the use
of antiplatelet therapy.9 The use of DAPT
instead of aspirin alone has been the
most commonly used trend after being
translated from the cardiology literature.10 Nevertheless, there is no standard
protocol to define the dose, duration, and
the combination of the antiplatelet drugs
used in the setting of PED placement.11
In our study, 10.8% of patients in the
bolus group suffered from thromboembolic complications compared with 6.3%
of the maintenance group. A total of 17
patients from the bolus group manifested
with thromboembolic events within less
than 1-month follow-up: only 4 of them
had a major permanent neurologic
deficit ranging from extremity weakness
to complete hemiparesis, whereas the
other 13 patients had minor transient
neurologic symptoms, such as visual
floaters, minimal limb weakness, and
numbness or speech difficulty, that
completely resolved on latest follow-up
(mRS <1). The latter results are somehow
predictable as they reflect the pharmacodynamic properties of clopidogrel.
Platelet function assays done ex vivo
revealed a measurable antiplatelet effect
starting within 60 minutes and reaching
a maximum of antiplatelet inhibition 2
hours after the 600-mg loading dose of
clopidogrel.12-14 The rates of thromboembolic events seen in the clopidogrel
bolus group would be precipitated by the
complex pathophysiology of thromboembolic events even when the patient is
under an optimal antiplatelet regimen.
This clopidogrel regimen would be
addressing one single step in the primary
hemostasis (platelet aggregation) process
and sometimes might turn out to be
insufficient for complete and definite
protection of the patient from these
complications.
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The rate of hemorrhagic complications
in the clopidogrel bolus group was 7.6%
compared with 3.75% in the clopidogrel pretreatment maintenance dose.
Leung et al.15 suggested that patients
with acute ischemic strokes receiving
clopidogrel loading doses within 24
hours of symptom onset did not have
a greater rate of new serious bleeding
events compared with patients who did
not receive loading doses. Nonetheless,
we will wait the results of the PlateletOriented Inhibition in New TIA and Minor
Ischemic Stroke trial to confirm the safety
of clopi- dogrel dosing in this group.16
Nonetheless, 4 patients receiving bolus
precipitated intracerebral hemorrhage
postprocedurally. One died, and 3 had
small right temporal and frontal bleeding,
who ended up having minimal neurologic
sequelae (mRS 2). Eight other patients
from the same group manifested SAH
postprocedurally. Three had minor SAH
with minimal neurosequelae (mRS 2) on
latest follow-up, and the remaining 5
patients died subsequently due to major
SAH: 2 of them died the first week after
their intervention, and the last 3 died 1 or
2 months postprocedurally. Even if our
statistical analysis does not show any
significant difference in hemorrhagic
complication between both groups, it
is noteworthy to emphasize the greater
rate of hemorrhagic events in the bolus
group. Whether the clopidogrel loading
dose increased the rate of hemorrhage
in our series cannot be inferred from
our descriptive study design, and further
prospective studies are needed for to
confirm these observations.
To our knowledge, there is only one study
reflecting a head-to-head comparison
between clopidogrel pretreatment
protocol and high loading dose in cardiovascular literature, as percutaneous
coronary intervention (PCI) is almost
always done during emergencies.17 In
this randomized, double-blinded, clinical
trial, Nguyen et al.17 compared different
maintenance doses of clopidogrel given
a week before PCI (75 mg once daily vs.
150 mg once daily after 300-mg loading
dose each) and loading doses (300 mg
vs. 600 mg) given 1 day before the procedure. They concluded that a loading
standard dose of 300 mg of clopidogrel
followed by a 150-mg daily maintenance
dose given a week before PCI achieved
better platelet inhibition and low reactivity

than the 300-mg loading dose given 24
hours before the procedure. How- ever,
the 600-mg loading dose given a day
before PCI was not statistically inferior to
the 300-mg/150-mg daily maintenance
dose.
The results from the Antiplatelet
therapy for Reduction of Myocardial
Damage during Angioplasty (ARMYDA-8
RELOAD- ACS) trial have shown a statistically significant advantage of reloading
patients with acute coronary syndrome
who were already on chronic clopidogrel therapy (75 mg) with a loading dose
of 600 mg of clopidogrel before PCI.18
The reloading strategy was associated
with a 66% relative risk reduction of
30-day major adverse cardiac events.18
Whether this additional advantage is due
exclusively to added inhibition of platelet
aggregation is not well established. A
study conducted by Patti et al.19 indicates
that a clopidogrel loading dose (600
mg or 300 mg) before PCI decreases
procedural P-selectin levels. P-selectin
is a marker of platelet activation and
may directly contribute to the stability
of platelet aggregates.20 It also may be
partly responsible for mechanisms linking
inflammation and thrombosis.21 This may
suggest that the benefits of the loading
dose strategy are not just exclusive to the
inhibition of adenosine diphosphateeinduced platelet aggregation. Many other
studies demonstrated the advantage of
giving a high-loading dose (600 mg) of
clopidogrel before PCI compared with
the standard 300-mg dose.19,22-24 Also,
the clinical trial done by Nguyen et al.
did not show any superiority of an even
high pretreatment maintenance dose of
clopidogrel preceded by 300-mg bolus
1 week before PCI compared with the
600-mg loading dose 1 day before the
procedure.17 It is also noteworthy to
mention that in our study population,
<20% of the patients were female, and our
overall aneurysm distribution by sex was
not typically skewed towards males. We
do not know how this finding could have
affected our results. Further prospective
studies are needed to uncover a possible
association between sex and pipeline
treatment complications.
Whether all these results infer superiority of the 600-mg loading dose of
clopidogrel before PED to the 75-mg
maintenance dose given a week before
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the procedure cannot be determined at
this time. Most of the studies in which
authors compared the efficacy and
safety of different doses of clopidogrel
were extrapolated from cardiac studies
and cannot be directly translated to
cerebrovascular settings. Also, no headto-head comparison was done between
the 1-week pretreatment maintenance
dose of clopidogrel with the 600-mg
loading dose 24 hours before PED. This
comparison was not done in the present
study, and no definite conclusions can
be derived at this point. Our study is
the first descriptive observational study
that compared the different outcomes
between the 600-mg loading dose and
the pretreatment 75-mg maintenance
dose used in patients undergoing PED.
Our study remains limited by the retrospective nature of the data collection:
the patients were not selected randomly
for bolus versus pretreatment. Such a
limitation must be addressed in further
large prospective studies. Although no
direct clinical suggestions can be derived
from this study, we believe it is a first step
towards higher-evidence studies to come
out with a standard regimen of DAPT.

CONCLUSIONS
Aspirin/clopidogrel DAPT routinely is
recommended for patients 7e10 days
before receiving neurovascular PED
treatment. Never- theless, patients
presenting with ruptured aneurysms,
those who could have not received a
standard 10 days DAPT protocol, or
those showing nonsatisfactory platelet
inhibition at admission can be selected
for an acute antiaggregation protocol:
a 600-mg loading dose of clopidogrel
might be safe and efficacious in reaching
the optimal platelet inhibition within 24
hours of the pipeline deployment.
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